The pharma sector has faced multiple headwinds in the last few quarters. However, the sector’s outlook appears to be improving as raw material and logistics costs are seeing a softening trend which will help reduce operational costs. Analysts expect price erosion in the US market to reduce to a single digit in 2022-23, which will help support the profitability. Param Desai, Research Analyst, Prabhudas Lilladher, says: “US base business will